Meeder Asset Management Inc Ironwood Pharmaceuticals Inc Transaction History

Meeder Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$10.14 - $12.38 $3,721 - $4,543	367 New	367 $4,000
Q1 2020 May 15, 2020	SELL	$8.58 - $14.01 $9,592 - $15,663	-1,118 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$8.22 - $14.0 $4,553 - $7,756	-554 Reduced 33.13%	1,118 $15,000
Q3 2019 Oct 17, 2019	BUY	$8.59 - $10.96 $13,245 - $16,900	1,542 Added 1186.15%	1,672 $14,000
Q2 2019 Aug 05, 2019	SELL	$9.8 - $12.89 $9,996 - $13,147	-1,020 Reduced 88.7%	130 $1,000
Q1 2019 Apr 16, 2019	BUY	$8.27 - $12.73 $5,673 - $8,732	686 Added 147.84%	1,150 $16,000
Q4 2018 Jan 17, 2019	SELL	$7.8 - $16.13 $104,325 - $215,738	-13,375 Reduced 96.65%	464 $5,000
Q3 2018 Nov 02, 2018	BUY	$14.31 - $17.65 $59,186 - $73,000	4,136 Added 42.63%	13,839 $0
Q2 2018 Jul 24, 2018	BUY	$11.83 - $16.2 $114,786 - $157,188	9,703 New	9,703 $0

231

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $322M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.